Financial Snapshot

Revenue
$21.32M
TTM
Gross Margin
Net Earnings
-$23.94M
TTM
Current Assets
$92.41M
Q3 2024
Current Liabilities
$39.64M
Q3 2024
Current Ratio
233.13%
Q3 2024
Total Assets
$106.9M
Q3 2024
Total Liabilities
$81.87M
Q3 2024
Book Value
$24.98M
Q3 2024
Cash
P/E
-14.96
Nov 29, 2024 EST
Free Cash Flow
-$34.25M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue $9.525M $4.802M $2.397M $9.450M $1.930M $5.760M $1.500M $1.830M $3.240M $310.0K $120.0K $20.00K
YoY Change 98.35% 100.33% -74.63% 389.64% -66.49% 284.0% -18.03% -43.52% 945.16% 158.33% 500.0%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue $9.525M $4.802M $2.397M $9.450M $1.930M $5.760M $1.500M $1.830M $3.240M $310.0K $120.0K $20.00K
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

No data

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Selling, General & Admin $15.72M $18.22M $16.73M $13.12M $12.42M $12.31M $10.66M $9.210M $6.780M $6.500M $790.0K $160.0K
YoY Change -13.73% 8.89% 27.52% 5.64% 0.89% 15.48% 15.74% 35.84% 4.31% 722.78% 393.75%
% of Gross Profit
Research & Development $23.15M $50.87M $40.53M $36.35M $44.91M $28.79M $30.32M $31.02M $23.04M $10.15M $2.550M $290.0K
YoY Change -54.48% 25.51% 11.49% -19.06% 55.99% -5.05% -2.26% 34.64% 127.0% 298.04% 779.31%
% of Gross Profit
Depreciation & Amortization $2.513M $2.521M $2.329M $2.360M $2.050M $990.0K $1.070M $1.250M $480.0K $130.0K $20.00K $0.00
YoY Change -0.32% 8.24% -1.31% 15.12% 107.07% -7.48% -14.4% 160.42% 269.23% 550.0%
% of Gross Profit
Operating Expenses $41.38M $50.87M $59.59M $51.82M $59.38M $42.05M $41.99M $41.40M $30.24M $16.77M $3.360M $440.0K
YoY Change -18.64% -14.64% 14.99% -12.73% 41.21% 0.14% 1.43% 36.9% 80.32% 399.11% 663.64%
Operating Profit
YoY Change

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Interest Expense $2.088M $1.311M -$4.372M -$4.120M $830.0K -$790.0K -$3.180M $470.0K $6.170M $4.330M -$10.00K $0.00
YoY Change 59.27% -129.99% 6.12% -596.39% -205.06% -75.16% -776.6% -92.38% 42.49% -43400.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

No data

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Pretax Income -$27.81M -$64.80M -$61.56M -$46.49M -$56.61M -$37.09M -$43.67M -$39.10M -$20.83M -$12.13M -$3.250M -$420.0K
YoY Change -57.08% 5.25% 32.42% -17.88% 52.63% -15.07% 11.69% 87.71% 71.72% 273.23% 673.81%
Income Tax -$78.00K $96.00K $117.0K $120.0K $130.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$28.12M -$64.89M -$61.62M -$46.57M -$56.48M -$36.89M -$43.64M -$39.10M -$20.83M -$12.13M -$3.250M -$420.0K
YoY Change -56.67% 5.31% 32.32% -17.55% 53.1% -15.47% 11.61% 87.71% 71.72% 273.23% 673.81%
Net Earnings / Revenue -295.21% -1351.33% -2570.76% -492.8% -2926.42% -640.45% -2909.33% -2136.61% -642.9% -3912.9% -2708.33% -2100.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.35 -$0.91 -$960.1K -$930.3K -$1.376M -$1.083M -$1.720M -$1.675M -$892.5K -$519.7K -$155.1K -$20.04K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Cash & Short-Term Investments $118.9M $94.78M $187.5M $75.80M $112.0M $105.6M $48.10M $59.20M $94.90M $112.7M $4.100M $200.0K
YoY Change 25.48% -49.46% 147.39% -32.32% 6.06% 119.54% -18.75% -37.62% -15.79% 2648.78% 1950.0%
Cash & Equivalents $0.00 $0.00 $105.6M
Short-Term Investments
Other Short-Term Assets $1.316M $3.056M $3.691M $3.800M $2.400M $1.800M $2.400M $1.700M $2.400M $800.0K $100.0K $0.00
YoY Change -56.94% -17.2% -2.87% 58.33% 33.33% -25.0% 41.18% -29.17% 200.0% 700.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $121.0M $154.5M $191.5M $80.00M $114.7M $108.4M $50.60M $62.00M $97.80M $113.9M $4.300M $300.0K
YoY Change -21.67% -19.33% 139.35% -30.25% 5.81% 114.23% -18.39% -36.61% -14.14% 2548.84% 1333.33%
Property, Plant & Equipment $16.90M $16.24M $17.47M $18.60M $2.400M $1.900M $2.500M $3.400M $2.200M $1.200M $200.0K $0.00
YoY Change 4.05% -7.02% -6.09% 675.0% 26.32% -24.0% -26.47% 54.55% 83.33% 500.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $621.0K $629.0K $100.0K $400.0K
YoY Change -100.0% -1.27% 529.0% -75.0%
Other Assets
YoY Change
Total Long-Term Assets $16.90M $16.86M $18.10M $18.70M $2.800M $1.800M $2.500M $3.500M $2.300M $1.300M $200.0K $0.00
YoY Change 0.21% -6.82% -3.23% 567.86% 55.56% -28.0% -28.57% 52.17% 76.92% 550.0%
Total Assets $137.9M $171.3M $209.6M $98.70M $117.5M $110.2M $53.10M $65.50M $100.1M $115.2M $4.500M $300.0K
YoY Change
Accounts Payable $1.541M $392.0K $191.0K $200.0K $400.0K $100.0K $500.0K $300.0K $900.0K $1.200M $700.0K $100.0K
YoY Change 293.11% 105.24% -4.5% -50.0% 300.0% -80.0% 66.67% -66.67% -25.0% 71.43% 600.0%
Accrued Expenses $1.659M $1.118M $1.230M $0.00 $100.0K $0.00 $1.000M $300.0K $200.0K $300.0K $0.00 $0.00
YoY Change 48.39% -9.11% -100.0% -100.0% 233.33% 50.0% -33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.614M $3.887M $6.305M $2.400M $900.0K $0.00 $2.000M $0.00 $0.00 $0.00 $2.500M $0.00
YoY Change -58.48% -38.35% 162.71% 166.67% -100.0% -100.0%
Total Short-Term Liabilities $34.20M $21.11M $27.60M $10.30M $11.00M $8.200M $8.500M $6.700M $5.500M $3.000M $3.600M $100.0K
YoY Change 62.01% -23.5% 167.92% -6.36% 34.15% -3.53% 26.87% 21.82% 83.33% -16.67% 3500.0%
Long-Term Debt $18.12M $18.08M $54.07M $31.90M $12.70M $9.400M $5.300M $5.700M $4.800M $2.800M $1.000M $100.0K
YoY Change 0.2% -66.55% 69.49% 151.18% 35.11% 77.36% -7.02% 18.75% 71.43% 180.0% 900.0%
Other Long-Term Liabilities $44.17M $67.01M $14.69M
YoY Change -34.09% 356.27%
Total Long-Term Liabilities $62.29M $85.10M $68.75M $31.90M $12.70M $9.400M $5.300M $5.700M $4.800M $2.800M $1.000M $100.0K
YoY Change -26.8% 23.77% 115.53% 151.18% 35.11% 77.36% -7.02% 18.75% 71.43% 180.0% 900.0%
Total Liabilities $96.49M $105.8M $95.75M $41.60M $23.20M $17.30M $13.70M $12.40M $10.30M $5.800M $4.600M $200.0K
YoY Change -8.82% 10.53% 130.16% 79.31% 34.1% 26.28% 10.48% 20.39% 77.59% 26.09% 2200.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $358.12 Million

About ProQR Therapeutics N.V.

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 157 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Industry: Pharmaceutical Preparations Peers: LAVA Therapeutics NV Merus N.V. uniQure N.V.